Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Xenografts established from the clonal lines exhibited significant tumor control following MMC treatment (treated/control [T/C] 17% and 51% for DTD and P450R xenografts, respectively) that was not seen in wild-type tumors (T/C 102%).
|
14555709 |
2003 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
When the NQO1-proficient A549 tumors and NQO1-deficient MDA-MB-231 tumors were developed in the same animal, only the A549 malignancies activated the NIR-ASM probe with a strong signal.
|
31189950 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We show elevated NAD(P)H:quinone oxidoreductase-1 (NQO1) levels in tumors from NSCLC patients. beta-Lapachone, an effective chemotherapeutic and radiosensitizing agent, selectively killed NSCLC cells that expressed high levels of NQO1.
|
17609380 |
2007 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We measured expression levels of three different reductase enzymes-DT-diaphorase [NAD(P)H (i.e., reduced nicotinamide adenine dinucleotide, with or without phosphate): quinone oxidoreductase]; NADPH:cytochrome P-450 reductase; and NADH (i.e., reduced nicotinamide adenine dinucleotide): cytochrome-b5 reductase- in 69 cell lines (most of the National Cancer Institute [NCI] human tumor cell panel) to see if relationships could be established between the activities of these enzymes and cellular sensitivities to the bioreductive compounds mitomycin C and EO9.
|
8614004 |
1996 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We found that NQO1 was frequently up-regulated in human liver cancer, and its high expression level was correlated with the tumor stage and low survival rate of HCC patients.
|
30867140 |
2019 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This was transfected into the human colon BE tumor line, which has a disabling point mutation in NQO1.
|
11040064 |
2000 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to β-lap-induced radiosensitization.
|
27196777 |
2016 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This genomic gain was associated with amplification of the NQO1 gene in one tumor biopsy as well as in breast cancer cell lines.
|
26687450 |
2016 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
They can be activated by DT-diaphorase and hence can be used to target tumour types rich in this (O2)-independent reductase enzyme.
|
12052210 |
2002 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These results support the ideas that reductive activation of MMC by DTD may be important in the cytotoxicity of MMC and that polymerase chain reaction may be a useful technique for quantitating the relative expression of genes in human tumors.
|
1737339 |
1992 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that RH1 may be an effective NQO1-directed antitumor agent for the therapy of tumors with elevated NQO1 activity, such as NSCLC.
|
9865924 |
1998 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These data indicate that the NQO1 609C>T polymorphism results in significantly reduced tumor NQO1 activity and reduced survival in subsets of patients receiving intraperitoneal hyperthermic mitomycin C therapy.
|
11773862 |
2002 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, our findings support that NQO1 displays a paradoxical role in mediating GBM growth in response to tumor suppressor PTEN.
|
30595797 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The rate of strong positive NQO1 protein expression was correlated with large tumor size (P=0.019), late pathologic stage (P=0.001) and the presence of lymph node metastasis (P=0.001).
|
25231218 |
2014 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The present study did not find any significant association of NQO1 609C>T and NQO2 -3423G>A polymorphisms with susceptibility to EC or its clinical phenotypes (histopathology, tumor location or lymph node metastasis) or interactions with lifestyle risk factors (tobacco usage, smoking, alcohol habit and occupational exposures).
|
22770696 |
2012 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The positive rate of NQO1 was related with clinical stage and lymph node metastasis, and the strongly positive rate of NQO1 protein was significantly correlated with tumor size, poor differentiation, advanced clinical stage and lymph node metastasis in NSCLC.
|
25880877 |
2015 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The FANCD2-associated survival effect was most pronounced in hormone receptor positive, HER2-negative tumors, and in tumors with above-median NQO1 expression.
|
23897704 |
2013 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Secondary objectives were assessment of toxicity, pharmacokinetic determination of RH1 and pharmacodynamic assessment of drug effect through measurement of DNA cross linking in peripheral blood mononuclear cells (PBMCs) and tumour, DTD activity in tumour and NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphism status.
|
21378203 |
2011 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Releasing β-lapachone first from the CARNs selectively increases the ROS level in cancer cells via NAD(P)H:quinone oxidoreductase-1 (NQO1) catalysis, which induces the cascade amplification release of DOX and overcomes multidrug resistance (MDR) in cancer cells, producing a remarkably improved therapeutic efficacy against MDR tumors with minimal side effects.
|
28833669 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Release of Lapa selectively increases tumor site-specific generation of H<sub>2</sub>O<sub>2</sub> via NAD(P)H: quinone oxidoreductase 1 (NQO1) catalysis.
|
31397998 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Quinone oxidoreductase (DT-diaphorase) levels rise in the human tumors but fall in the mouse; the extent of both changes is very dramatic.
|
9659582 |
1998 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Protection from tumor formation is associated with elevation of Phase II enzymes, including glutathione (GSH) transferase and NAD(P)H:quinone oxidoreductase (DT-diaphorase) in experimental carcinogenesis models in vivo.
|
9815750 |
1997 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Previous studies have shown that depleting tumor-NQO1 potentiates anoikis and inhibits growth of NSCLC.
|
29291405 |
2018 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our data showed that (1) the frequency of C609T NQO1 was significantly increased in TNM stage III HCC patients; (2) no significant association was found between p53 expression and C609T polymorphism of NQO1 gene; and (3) a tumor/non-tumor (T/N) ratio > 1.27 of NQO1 expression revealed by real-time qPCR analyses was positively correlated with poorer survival in patients with tumors >5 cm, suggesting that an increase of NQO1 expression may be an indicator of advanced tumor progression.
|
19688691 |
2009 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Notably, NQO1 inhibitor significantly enhanced the antitumor effects of THC in ESCC PDX tumors.
|
30737573 |
2019 |